Sponsor or institution
Clinical trials and research at Supernus Pharmaceuticals, Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Supernus Pharmaceuticals, Inc. that are recruiting, at sites in 5 countries (most in United States (5), Australia (2), Bulgaria (1)). By phase: Phase 2 (3), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Double-blind, placebo-controlled test of SPN-821 in adults with major depressive disorder | Phase 2 | Birmingham, Alabama and 39 other locations | Recruiting | Nov 10, 2025 |
| Real-world experiences with ONAPGO continuous subcutaneous apomorphine infusion for Parkinson's disease in the U.S. | — | Aliso Viejo, California and 4 other locations | Recruiting | Oct 22, 2025 |
| Evaluating SPN-817 for adults with focal onset seizures | Phase 2 | Phoenix, Arizona and 62 other locations | Recruiting | Jan 29, 2025 |
| SPN-817 for adults with treatment-resistant epilepsy | Phase 2 | Jacksonville, Florida and 9 other locations | Recruiting | Aug 26, 2022 |
| Evaluating a medication for preschool children with ADHD | Phase 4 | Saraland, Alabama and 53 other locations | Recruiting | Mar 4, 2021 |
All recruiting trials (5)
-
Double-blind, placebo-controlled test of SPN-821 in adults with major depressive disorder
This trial will test whether adding SPN-821 twice weekly to an approved antidepressant helps adults with major depressive disorder who have not had enough improvement.
-
Real-world experiences with ONAPGO continuous subcutaneous apomorphine infusion for Parkinson's disease in the U.S.
This project will collect real-world experiences to see how continuous subcutaneous ONAPGO infusion works for people with Parkinson's disease who have been prescribed it in the United States.
-
Evaluating SPN-817 for adults with focal onset seizures
This study is testing a new medication called SPN-817 to see if it can help adults with focal onset seizures who haven't found relief from other treatments.
-
SPN-817 for adults with treatment-resistant epilepsy
We will try SPN-817 to see if it is safe and tolerable for adults whose seizures haven't responded to standard treatments.
-
Evaluating a medication for preschool children with ADHD
This study is testing a new medication for preschool children with ADHD to see if it helps them manage their symptoms better than a placebo.
Quick answers
How many clinical trials run by Supernus Pharmaceuticals, Inc. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in United States (5 trials), Australia (2 trials), Bulgaria (1 trial), Hungary (1 trial), Poland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.